CN102834408A - 芳香族阳离子肽及其用途 - Google Patents

芳香族阳离子肽及其用途 Download PDF

Info

Publication number
CN102834408A
CN102834408A CN2011800071355A CN201180007135A CN102834408A CN 102834408 A CN102834408 A CN 102834408A CN 2011800071355 A CN2011800071355 A CN 2011800071355A CN 201180007135 A CN201180007135 A CN 201180007135A CN 102834408 A CN102834408 A CN 102834408A
Authority
CN
China
Prior art keywords
lys
dmt
arg
phe
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800071355A
Other languages
English (en)
Chinese (zh)
Inventor
黑兹尔·H·司徒
彼得·W·席勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montreal Clinical Research Institute
Cornell University
Original Assignee
Montreal Clinical Research Institute
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montreal Clinical Research Institute, Cornell University filed Critical Montreal Clinical Research Institute
Publication of CN102834408A publication Critical patent/CN102834408A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2011800071355A 2010-01-25 2011-01-24 芳香族阳离子肽及其用途 Pending CN102834408A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29806210P 2010-01-25 2010-01-25
US61/298,062 2010-01-25
PCT/US2011/022247 WO2011091357A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510081030.4A Division CN104725472A (zh) 2010-01-25 2011-01-24 芳香族阳离子肽及其用途

Publications (1)

Publication Number Publication Date
CN102834408A true CN102834408A (zh) 2012-12-19

Family

ID=44307257

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800071355A Pending CN102834408A (zh) 2010-01-25 2011-01-24 芳香族阳离子肽及其用途
CN201510081030.4A Pending CN104725472A (zh) 2010-01-25 2011-01-24 芳香族阳离子肽及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510081030.4A Pending CN104725472A (zh) 2010-01-25 2011-01-24 芳香族阳离子肽及其用途

Country Status (8)

Country Link
US (6) US20120329730A1 (cg-RX-API-DMAC10.html)
EP (4) EP2528934A4 (cg-RX-API-DMAC10.html)
JP (2) JP2013518057A (cg-RX-API-DMAC10.html)
CN (2) CN102834408A (cg-RX-API-DMAC10.html)
AU (2) AU2011207432A1 (cg-RX-API-DMAC10.html)
CA (2) CA2787331A1 (cg-RX-API-DMAC10.html)
HK (1) HK1208686A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011091357A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105939759A (zh) * 2013-12-02 2016-09-14 康德生物医疗技术公司 用于治疗白癜风的组合物和方法
CN107530395A (zh) * 2015-03-06 2018-01-02 康德生物医疗技术公司 制备药物相关肽的方法
CN113383005A (zh) * 2018-12-18 2021-09-10 隐形生物治疗公司 靶向线粒体疾病的类似物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3708178T1 (sl) * 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP2013532124A (ja) * 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
US20150119552A1 (en) * 2012-04-12 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
CA2920735A1 (en) * 2013-08-12 2015-02-19 Stealth Biotherapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP6533723B2 (ja) * 2015-09-11 2019-06-19 キユーピー株式会社 抗酸化剤
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3010321A1 (en) * 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
WO2017156403A1 (en) * 2016-03-11 2017-09-14 Stealth Biotherapeutics Crystalline salt forms
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
EP3681900A4 (en) * 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A2 (en) * 2003-02-04 2004-08-19 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0273696A2 (en) * 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
HUT58763A (en) * 1989-11-06 1992-03-30 Erba Carlo Spa Process for producing reduced irreverzible bombezin antagonists and pharmaceutical compositions containing them as active components
EP0592512A1 (en) * 1991-07-01 1994-04-20 University Technologies International Inc. (Uti) NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A2 (en) * 2003-02-04 2004-08-19 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105939759A (zh) * 2013-12-02 2016-09-14 康德生物医疗技术公司 用于治疗白癜风的组合物和方法
CN105939759B (zh) * 2013-12-02 2020-01-17 康德生物医疗技术公司 用于治疗白癜风的组合物和方法
CN107530395A (zh) * 2015-03-06 2018-01-02 康德生物医疗技术公司 制备药物相关肽的方法
CN107530395B (zh) * 2015-03-06 2021-10-22 康德生物医疗技术公司 制备药物相关肽的方法
CN113383005A (zh) * 2018-12-18 2021-09-10 隐形生物治疗公司 靶向线粒体疾病的类似物

Also Published As

Publication number Publication date
EP2848628A1 (en) 2015-03-18
EP2733150A1 (en) 2014-05-21
AU2011207432A1 (en) 2012-08-02
US20180244721A1 (en) 2018-08-30
US20150005242A1 (en) 2015-01-01
WO2011091357A1 (en) 2011-07-28
HK1208686A1 (en) 2016-03-11
US20130316964A1 (en) 2013-11-28
JP2013518057A (ja) 2013-05-20
EP2528934A4 (en) 2013-08-21
EP2528934A1 (en) 2012-12-05
CN104725472A (zh) 2015-06-24
CA2787331A1 (en) 2011-07-28
US20120329730A1 (en) 2012-12-27
EP3018138A1 (en) 2016-05-11
US20190330272A1 (en) 2019-10-31
CA3008993A1 (en) 2011-07-28
AU2016200747A1 (en) 2016-02-25
US20170008925A1 (en) 2017-01-12
JP2016000750A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
US20190330272A1 (en) Aromatic-cationic peptides and uses of same
CA2776581C (en) Methods for the prevention or treatment of heart failure
US11083772B2 (en) Methods and compositions for the prevention or treatment of Barth Syndrome
CN116474071A (zh) 治疗线粒体疾病的方法
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
EP2712620A1 (en) Methods for Preventing or Treating Insulin Resistance
US20170057995A1 (en) Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
US20200308220A1 (en) Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
HK1179977A (en) Aromatic-cationic peptides and uses of same
AU2019392670A1 (en) Methods and compositions for the treatment of Sengers syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179977

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121219